BioSpace News Archive

Insmed Incorporated Inc. today announced that management will participate in the virtual investor conferences.

Authorization to conduct INNOVATE Phase 3 trial in India builds on recent regulatory authorizations from Brazil, Philippines, Mexico and Colombia

Apollo Medical Holdings, Inc., a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, announced that the Company’s affiliate has entered into an agreement to purchase within three years all of the remaining equity interests in Diagnostic Medical Group of Southern California.

Ipsen (Euronext: IPN; ADR: IPSEY) announced today the appointment of Stewart Campbell as Executive Vice President and President of North America, effective immediately.

EpiVax Therapeutics, Inc today announced that an abstract highlighting its Ancer® platform will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting from November 12-14, 2021 in Washington, DC

PhaseBio Pharmaceuticals, Inc. today announced topline data from its Phase 2b clinical trial of bentracimab, which was conducted in healthy, older volunteers 50-80 years old.

Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended September 30, 2021, and provided an update on the Company’s clinical development programs and regulatory and commercial outlook.

Veracyte, Inc. (Nasdaq: VCYT) announced today the publication of new long-term clinical utility data showing that the company’s Afirma Genomic Sequencing Classifier (GSC) helped reduce unnecessary surgeries in patients with indeterminate thyroid nodule cytology

Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that the Company will report its third quarter 2021 financial results and provide a corporate update on Wednesday, November 10, 2021.

Minerva Neurosciences, Inc. today announced that the U. S. Food and Drug Administration (FDA) has denied the company’s request for a pre-NDA meeting for roluperidone and responded that a Type C guidance meeting would be more appropriate to discuss the evidence for use of roluperidone as monotherapy.